Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade

Hypertension Research

Volumn 31, Issue 3, 2008, Pages 553-559

  Igase, Michiya ^a   Kohara, Katsuhiko ^a   Nagai, Tokihisa ^a   Miki, Tetsuro ^a   Ferrario, Carlos M ^b  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme 2; Angiotensin type 1 receptor antagonist; Angiotensin 1 7; Spontaneously hypertensive rat; Vascular remodelling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE; DRINKING WATER; OLMESARTAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERY INTIMA; ARTICLE; CAROTID ARTERY; CAROTID ARTERY INJURY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; RAT; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT DURATION; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, ABDOMINAL; BALLOON DILATATION; BLOOD PRESSURE; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; HEART RATE; HYPERPLASIA; HYPERTENSION; IMIDAZOLES; MALE; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TUNICA INTIMA;

EID: 42649136964     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.553     Document Type: Article

References (31)

1. Windecker S, Remondino A, Eberli FR, et al: Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662.
2. Bult H: Restenosis: a challenge for pharmacology. Trends Pharmacol Sci 2000; 21: 274-279.
3. Kim S, Kawamura M, Wanibuchi H, et al: Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation 1995; 92: 88-95.
4. Donoghue M, Hsieh F, Baronas E, et al: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
5. Harmer D, Gilbert M, Borman R, Clark KL: Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107-110.
6. Hamming I, Timens W, Bulthuis ML, et al: Tissue distribution of ACE2 protein, functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631-637.
7. Igase M, Strawn WB, Gallagher PE, et al: Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289: H1013-H1019.
8. Crackower MA, Sarao R, Oudit GY, et al: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828.
9. Chappell MC, Ferrario CM, Tallant EA: Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 2004; 143: 77-89.
10. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM: Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31: 699-705.
11. Strawn WB, Ferrario CM, Tallant EA: Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207-211.
12. Igase M, Okura T, Kitami Y, Hiwada K: Apoptosis and Bclxs in the intimal thickening of balloon-injured carotid arteries. Clin Sci 1999; 96: 605-612.
13. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM: Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 2003; 108: 2141-2146.
14. Brosnihan KB, Neves LA, Joyner J, et al: Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension 2003; 42: 749-753.
15. Iwai N, Izumi M, Inagami T, et al: Induction of renin in medial smooth muscle cells by balloon injury. Hypertension 1997; 29: 1044-1050.
16. Rakugi H, Kim DK, Krieger JE, et al: Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 1994; 93: 339-346.
17. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992; 86: 100-110.
18. Berger PB, Holmes DR Jr, Ohman EM, et al: Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). J Am Coll Cardiol 1996; 27: 1-7.
19. Urata H, Nishimura H, Ganten D: Mechanisms of Ang II formation in humans. Eur Heart J 1995; 16: 79-85.
20. Peters S, Gotting B, Trummel M, et al: Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13: 93-97.
21. Widdop RE, Matrougui K, Levy BI, Henrion D: AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002; 40: 516-520.
22. Akishita M, Horiuchi M, Yamada H, et al: Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2000; 24: 13-20.
23. Suzuki J, Iwai M, Nakagami H, et al: Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 2002; 106: 847-853.
24. Matsubara H: Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998; 83: 1182-1191.
25. Ishiyama Y, Gallagher PE, Averill DB, et al: Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43: 970-976.
26. Yokoyama H, Averill DB, Brosnihan KB, et al: Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens 2005; 18: 922-929.
27. Yagi S, Morita T, Katayama S: Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004; 27: 129-135.
28. Grobe JL, Mecca AP, Lingis M, et al: Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007; 292: H736-H742.
29. Santos RA, Simoes e Silva AC, et al: Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263.
30. Tallant EA, Ferrario CM, Gallagher PE: Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005; 289: H1560-H1566.
31. Agata J, Ura N, Yoshida H, et al: Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006; 29: 865-874.